ArticleCVIR endovascular2026
Physician-modified endografts using an endoskeleton ePTFE platform for complex aortic aneurysms requiring a single fenestration: a proof-of-concept study.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndovascular interventions for complex aortic aneurysms-including juxtarenal abdominal aortic (JAAA), pararenal abdominal aortic (PRAAA), and thoracoabdominal aortic (TAAA) aneurysms-face inherent limitations, such as manufacturing delays and anatomical restrictions. In Japan, where commercial off-the-shelf branched or fenestrated devices remain limited, physician-modified endografts (PMEGs) represent a crucial practical alternative. Conventional polyester-based PMEGs, however, pose challenges regarding manual resheathing and fenestration site fragility. This study evaluated the safety and early- to mid-term clinical outcomes of PMEGs constructed using the endoskeleton-based, expanded polytetrafluoroethylene (ePTFE)-covered AFX VELA platform.
methodsThis retrospective study included four high-risk patients with complex aortic aneurysms requiring a single fenestration. All were unsuitable for open surgical repair (OSR), standard endovascular aneurysm repair (EVAR), or chimney endovascular aneurysm repair (ChEVAR) due to an infrarenal neck length (IRL) < 2 mm. Fenestrations were created via sharp ePTFE incision and reinforced with an expansile hydrogel coil. Following manual resheathing without dedicated crimping tools, target vessel cannulation and bridging stent reconstruction were performed. Endpoints included technical success, 30-day major adverse events (MAEs), target vessel patency, endoleaks, sac diameter changes, and reinterventions.
resultsThe cohort (two men, two women; mean age, 73.0 years) presented with saccular aneurysms (one JAAA, two PRAAAs, and one Crawford type V TAAA). The mean maximum diameter was 54.3 mm, and all had an IRL of 0 mm. Technical success was 100%, with zero 30-day mortalities or MAEs. Over a 31.5-month mean follow-up, primary target vessel patency remained 100%, without endoleaks or required reinterventions. Aneurysm sac diameter regressed by 5 mm in two patients and remained stable in two. No aortic-related mortalities occurred.
conclusionsThis proof-of-concept study is the first to describe AFX VELA-based PMEGs and shows that the technique is feasible in carefully selected patients with complex aortic aneurysms. The procedure does not require dedicated crimping tools or complex resheathing maneuvers, whereas its mid- to long-term durability requires continued evaluation. Establishing a definitive clinical role will require larger prospective studies with extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.